Why Illumina (ILMN) Could Be an Impressive Growth Stock

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is Illumina, Inc. ILMN. This firm, which is in the Medical - Biomedical and Genetics industry, saw EPS growth of 43% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for earnings-per-share growth of 16.8%. Furthermore, the long-term growth rate is currently an impressive 21.5%, suggesting pretty good prospects for the long haul.

Illumina, Inc. Price and Consensus

Illumina, Inc. Price and Consensus

Illumina, Inc. price-consensus-chart | Illumina, Inc. Quote

And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 2.3%. Thanks to this rise in earnings estimates, ILMN has a Zacks Rank #2 (Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider ILMN. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for ILMN as well.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Illumina, Inc. (ILMN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research